Skip to Main Content

Paper Details

Systemic inhibition of PTPN22 augments anticancer immunity.
J Clin Invest
23
2021
CD8, CD8+, CD8+ T cells, M1-like phenotypes, MHC-II, PD1, PDL1, PTPN22, T cell receptor, T cells, TCR, autoimmune diseases, cancer, macrophage subpopulations, macrophages, mice, natural killer (NK) cells, of PTPN22, patients, protein tyrosine phosphatase non-receptor type 22, rs2476601, rs2476601 variant, tumors, tyrosine
Author NameAffiliation
Ludmila DanilovaSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Ludmila DanilovaSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Janey WangVanderbilt University Medical Center
Elana J FertigSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Joshua C DennyVanderbilt University Medical Center
Ben Ho ParkVanderbilt University Medical Center
Ben Ho ParkVanderbilt University Medical Center
Zhong-Yin ZhangPurdue University
Zhong-Yin ZhangPurdue University
Elizabeth M JaffeeSidney Kimmel Comprehensive Cancer Center, John Hopkins University
  • 1 - 10

Datasets

Release 1.2